Results 61 to 70 of about 4,499 (142)

Efeitos da associação propafenona - propofol na contratilidade miocárdica, freqüência cardíaca, fluxo coronariano e incidência de arritmia em corações isolados de ratos Effects of propafenone associated with propofol on myocardial contractility, heart rate, coronary flow, and the incidence of arrhythmia in isolated hearts of rats

Arquivos Brasileiros de Cardiologia, 2004
OBJETIVO: Estudar a influência da propafenona associada ao propofol na contratilidade miocárdica (dP/dt e freqüência cardíaca), fluxo coronariano e incidência de arritmia em corações isolados de ratos.
Nilcéa Leal de Moraes Assis, Otoni Moreira Gomes, Silvério Leonardo Macedo Garcia, Guilherme Gustavo do Valle   +3 more
doaj   +1 more source

Antiarrhythmic therapy effects on quality of life among patients with extrasystoles

Российский кардиологический журнал, 2008
To investigate antiarrhythmic therapy effectiveness, safety and impact on quality of life (QoL) among patients with symptomatic extrasystolia, a study was performed in 152 individuals, with 140 completing the study. Mean age of the patients was 57 years;
V. L. Doshchitsyn, O. A. Kramynina, E. V. Chernova, O. B. Karpunichev, O. V. Barysheva, E. Yu. Shatykhina, Yu. V. Bezborodova   +6 more
doaj  

Propafenone effect on inotropic myocardial function in patients with recurrent atral fibrillation

Кардиоваскулярная терапия и профилактика, 2006
Aim. To study the effects of three-month propafenone antiarrhythmic therapy (daily dose 450 mg) on inotropic myocardial function in patients with recurrent atrial fibrillation (AF). Material and methods.
I. G. Fomina, A. I. Tarzimanova, A. V. Vetluzhsky   +2 more
doaj  

Ensanchamiento del complejo QRS: ¿hiperkalemia? ¿propafenona?

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2012
RESUMEN La hiperkalemia y la propafenona  son condiciones que enlentecen la velocidad de conducción intracardiaca. Se presenta  una paciente que en el curso de una hiperkalemia moderada y con dosis bajas de propafenona mostró una taquicardia sinusal con
Marleny Cruz Cardentey, Margarita Dorantes Sánchez, Annerys Méndez Rosabal   +2 more
doaj  

Choosing a class IC antiarrhythmic drug for the treatment of patients without structural heart disease: clinical advantages of the most common agents (literature review)

Сучасні медичні технології
Aim: to analyze the pharmacological features and updated evidence-based medicine data of Class IC antiarrhythmic drug (AAD) ethacizine compared to propafenone to optimize the choice of treatment for cardiac arrhythmias in patients without structural ...
N. M. Sydorova, M. Yu. Kolesnyk
doaj   +1 more source

Reduced progression of atrial fibrillation in hypertensive patients with long-term treatment of propafenone

КардиоСоматика, 2016
In recent years, progress has been made in the study of the natural history of atrial fibrillation (AF) - that, from the stage of having no clinical manifestations, to the final stage, which is an irreversible arrhythmia, is associated with the ...
A. I Tarzimanova, V. I Podzolkov
doaj  

Propafenon [PDF]

, 2018
C. Vidal, W. -R. Külpmann
openaire   +1 more source

Results of propafenone use in early postoperative period after pulmonary veins catheter radiofrequency isolation for prevention of early atrial tachyarrhythmias

КардиоСоматика, 2015
Currently pulmonary veins isolation becomes one of the approaches for invasive treatment of paroxysmal atrial fibrillation (AF). One of difficult and unexplored problems associated with this procedure is management of patients in postoperative period ...
A. V Tarasov, K. V Davtian, M. M Makhinova   +2 more
doaj  

Flecainide Provides Comparable Rhythm Control Efficacy to Repeat Radiofrequency Ablation in Patients with Paroxysmal Atrial Fibrillation After Failed Cryoballoon Ablation. [PDF]

J Innov Card Rhythm Manag
Ardıç ML, Coskun H, Sumbul HE, Icen YK, Çetin AE, Koç M.   +5 more
europepmc   +1 more source

Propafenone Overdose Presenting With Brugada Phenocopy, QRS Widening, and Ventricular Fibrillation. [PDF]

JACC Case Rep
Xiong Q, Xie Y.
europepmc   +1 more source